Cynthia A. Jackevicius

Cynthia A. Jackevicius

Auto-generated profile, based on publicly available information

Cynthia A. Jackevicius

ICES, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CJCynthia A. Jackevicius
Cynthia A. Jackevicius
JTJack V. Tu
Jack V. Tu
JRJoseph S. Ross
Joseph S. Ross
DKDennis T. Ko
Dennis T. Ko
HKHarlan M. Krumholz
Harlan M. Krumholz
Ezetimibe lowers low-density lipoprotein cholesterol, but current lipid-lowering guidelines in the United States and Canada do not recommend it as a first option for either primary or secondary prevention. We sought to describe the adoption of ezetimibe relative to that of other lipid-lowering agents and compare its use in the two countries. We conducted a population-level, cohort study using data from January 2002 to December 2006, provided by IMS Health, to describe prescribing practices and expenditures for lipid-lowering agents and ezetimibe in the United States and Canada. From 2002 to 2006, the monthly number of prescriptions for lipid-lowering agents rose from 3719 to 7401 per 100,000 population in Canada and from 3927 to 6827 per 100,000 population in the United States. Of these prescriptions, the proportion for ezetimibe rose from 0.2% in 2003 to 3.4% in 2006 in Canada and from 0.1% in 2002 to 15.2% in 2006 in the United States. Statin use was relatively constant between 2002 and 2006 in Canada, whereas the proportion of statin prescriptions decreased from 86.5 to 80.8% in the United States. In 2006, the ratio of prescriptions for statins to those for ezetimibe was 26:1 in Canada and 5:1 in the United States. In 2006, expenditures for ezetimibe per 100,000 population were higher in the United States than in Canada by a factor of more than 4. Distinct patterns of use of ezetimibe emerged in the United States and Canada from 2002 to 2006, a difference that markedly altered the approach to the treatment of hyperlipidemia in the United States. The U.S. pattern increased overall costs, but the effect on clinical outcomes is uncertain.

23 March 2011 in JAMA
Verified
Journal Article
Open access
PDF file
CJCynthia A. Jackevicius
Cynthia A. Jackevicius
JTJack V. Tu
Jack V. Tu
JRJoseph S. Ross
Joseph S. Ross
DKDennis T. Ko
Dennis T. Ko
DCDaniel Carreon
Daniel Carreon
HKHarlan M. Krumholz
Harlan M. Krumholz
Health care reform has generated interest in identifying strategies to decrease health care costs without depriving patients of the health benefits of evidence-based therapies and generic formulations of drugs.1-3 The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial recently showed that fenofibrate plus statins in patients with type 2 diabetes did not reduce cardiovascular events more than use of statins alone.4 The only other fenofibrate study, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD), also failed to show reduced cardiovascular morbidity and mortality.5 These negative studies raise questions about a medication with more than $1 billion in sales in the United States.6

1 June 2014 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
CJCynthia A. Jackevicius
Cynthia A. Jackevicius
JLJennifer Le
Jennifer Le
LNLama Nazer
Lama Nazer
KHKarl Hess
Karl Hess
JWJeffrey Wang
Jeffrey Wang
ALAnandi V Law
Anandi V Law
To describe the development, implementation, and evaluation of a formal mentorship program at a college of pharmacy. After extensive review of the mentorship literature within the health sciences, a formal mentorship program was developed between 2006 and 2008 to support and facilitate faculty development. The voluntary program was implemented after mentors received training, and mentors and protégés were matched and received an orientation. Evaluation consisted of conducting annual surveys and focus groups with mentors and protégés. Fifty-one mentor-protégé pairs were formed from 2009 to 2012. A large majority of the mentors (82.8%-96.9%) were satisfied with the mentorship program and its procedures. The majority of the protégés (≥70%) were satisfied with the mentorship program, mentor-protégé relationship, and program logistics. Both mentors and protégés reported that the protégés most needed guidance on time management, prioritization, and work-life balance. While there were no significant improvements in the proteges' number of grant submissions, retention rates, or success in promotion/tenure, the total number of peer-reviewed publications by junior faculty members was significantly higher after program implementation (mean of 7 per year vs 21 per year, p=0.03) in the college's pharmacy practice and administration department. A formal mentorship program was successful as measured by self-reported assessments of mentors and protégés.

30 August 2023 in European Heart Journal
Verified
Journal Article
Closed access
HBHifza Buhari
Hifza Buhari
JFJiming Fang
Jiming Fang
LHLu Han
Lu Han
PAPeter C Austin
Peter C Austin
PDPaul Dorian
Paul Dorian
HAHusam Abdel-Qadir
Husam Abdel-Qadir
Background and aims: Female sex is associated with higher rates of stroke in atrial fibrillation (AF) after adjustment for other CHA2DS2-VASc factors. This study aimed to describe sex differences in age and cardiovascular care to examine their relationship with stroke hazard in AF. Methods: Population-based cohort study using administrative datasets of people aged ≥66 years diagnosed with AF in Ontario between 2007 and 2019. Cause-specific hazard regression was used to estimate the adjusted hazard ratio (HR) for stroke associated with female sex over a 2-year follow-up. Model 1 included CHA2DS2-VASc factors, with age modelled as 66–74 vs. ≥ 75 years. Model 2 treated age as a continuous variable and included an age–sex interaction term. Model 3 further accounted for multimorbidity and markers of cardiovascular care. Results: The cohort consisted of 354 254 individuals with AF (median age 78 years, 49.2% female). Females were more likely to be diagnosed in emergency departments and less likely to receive cardiologist assessments, statins, or LDL-C testing, with higher LDL-C levels among females than males. In Model 1, the adjusted HR for stroke associated with female sex was 1.27 (95% confidence interval 1.21–1.32). Model 2 revealed a significant age–sex interaction, such that female sex was only associated with increased stroke hazard at age >70 years. Adjusting for markers of cardiovascular care and multimorbidity further decreased the HR, so that female sex was not associated with increased stroke hazard at age ≤80 years. Conclusion: Older age and inequities in cardiovascular care may partly explain higher stroke rates in females with AF.

10 August 2015 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
CJCynthia A. Jackevicius
Cynthia A. Jackevicius
NLNoelle K. de Leon
Noelle K. de Leon
LLLingyun Lu
Lingyun Lu
DCDonald S. Chang
Donald S. Chang
AWAlberta L. Warner
Alberta L. Warner
FMFreny Vaghaiwalla Mody
Freny Vaghaiwalla Mody
Background: Specialized chronic heart failure (HF) clinics have demonstrated significant reductions in readmissions. Limited evidence is available regarding HF clinics in the immediate post-discharge period. Objective: To evaluate the effect of a multidisciplinary HF clinic on 90-day readmission rates and all-cause mortality in those recently discharged from a HF hospitalization. Methods: In this retrospective cohort study, patients discharged with a primary HF diagnosis who attended the HF postdischarge clinic in 2010-2012 were compared with controls from 2009. During 6 clinic visits, patients were seen by a physician assistant, clinical pharmacist specialist, and case manager, with care overseen by a cardiologist. The program focused on optimizing therapy, identifying HF etiology/precipitating factors, medication titration, education, and medication adherence. The primary outcome was 90-day HF readmission. A multivariate Cox proportional hazards model was used to compare outcomes. Results: Among the 277 patients (144 clinic, 133 control) in the study, 7.6% of patients in the clinic and 23.3% of patients in the control group were readmitted for HF within 90 days (aHR (adjusted hazard ratio) = 0.17; 95% CI = 0.07-0.41; P < 0.001; ARR (absolute risk reduction) = 15.7%; NNT (number needed to treat) = 7). Clinic patients had lower 90-day time-to-first HF readmission or all-cause mortality (9.0% vs 28.6%; aHR = 0.28; 95% CI = 0.06-0.31; P < 0.001; ARR = 19.6%; NNT = 6). Conclusions: The multidisciplinary HF posthospitalization outpatient program was associated with a significant reduction in 90-day HF readmissions in patients who were recently discharged from a HF hospitalization.

23 October 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CJCynthia A. Jackevicius
Cynthia A. Jackevicius
JTJack V. Tu
Jack V. Tu
VDVirginie Demers
Virginie Demers
MMMagda Melo
Magda Melo
JCJafna Cox
Jafna Cox
LPLouise Pilote
Louise Pilote
Drug-reimbursement policies may have an adverse effect on patient outcomes if they interfere with timely access to efficacious medications for acute medical conditions. Clopidogrel in combination with aspirin is the recommended standard of care for patients receiving coronary stents to prevent thrombosis. We examined the population-level effect of a change by a Canadian provincial government in a pharmacy-benefits program from a prior-authorization policy to a less restrictive, limited-use policy on access to clopidogrel among patients undergoing percutaneous coronary intervention (PCI) with stenting after acute myocardial infarction.